

## Special Issue

# Personalized Medicine in Brain Tumors

### Message from the Guest Editors

Brain tumors are a heterogeneous group including, among others, gliomas, neuronal tumors, embryonal tumors, meningiomas, other mesenchymal tumors, lymphomas, and sellar tumors. An increasing body of evidence points towards the biological heterogeneity of brain tumors, both at the cellular and molecular level. Accordingly, the upcoming 2021 WHO classification will expand an integrated histological-molecular approach, in which molecular data have a key role in establishing the correct diagnosis. From a therapeutic viewpoint, in some histologies, like lower-grade gliomas and medulloblastomas, such refined diagnosis has led to effective treatments. However, in other tumors, e.g., GBM, notwithstanding the huge advances in cellular and molecular profiling, novel therapeutics have failed to improve prognosis, which remains dismal. These issues foster an increased effort towards a personalized approach to brain tumors, in which a tailored treatment is administered based on the clinical, radiological, histopathological, biological, and molecular features of the single tumor.

### Guest Editors

**Prof. Roberto Pallini**

Department of Neurosurgery, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy

**Dr. Quintino Giorgio D'Alessandris**

Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli, 8, 00168 Rome, Italy

### Deadline for manuscript submissions

closed (25 July 2023)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/76022](https://mdpi.com/si/76022)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).